- Home
- HIMS vs PRCT Comparison
HIMS vs PRCT Comparison
Compare HIMS & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIMS
- PRCT
- Stock Information
- Founded
- HIMS 2017
- PRCT 2009
- Country
- HIMS United States
- PRCT United States
- Employees
- HIMS N/A
- PRCT N/A
- Industry
- HIMS Medical/Nursing Services
- PRCT Medical Specialities
- Sector
- HIMS Health Care
- PRCT Health Care
- Exchange
- HIMS Nasdaq
- PRCT Nasdaq
- Market Cap
- HIMS 6.6B
- PRCT 5.3B
- IPO Year
- HIMS N/A
- PRCT 2021
- Fundamental
- Price
- HIMS $26.19
- PRCT $81.17
- Analyst Decision
- HIMS Buy
- PRCT Strong Buy
- Analyst Count
- HIMS 14
- PRCT 7
- Target Price
- HIMS $23.71
- PRCT $97.86
- AVG Volume (30 Days)
- HIMS 16.7M
- PRCT 592.2K
- Earning Date
- HIMS 11-04-2024
- PRCT 10-28-2024
- Dividend Yield
- HIMS N/A
- PRCT N/A
- EPS Growth
- HIMS N/A
- PRCT N/A
- EPS
- HIMS 0.44
- PRCT N/A
- Revenue
- HIMS $1,241,994,000.00
- PRCT $199,843,000.00
- Revenue This Year
- HIMS $71.33
- PRCT $67.07
- Revenue Next Year
- HIMS $37.95
- PRCT $40.64
- P/E Ratio
- HIMS $58.94
- PRCT N/A
- Revenue Growth
- HIMS 56.70
- PRCT 71.71
- 52 Week Low
- HIMS $8.09
- PRCT $39.48
- 52 Week High
- HIMS $35.02
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- HIMS 44.33
- PRCT 33.77
- Support Level
- HIMS $24.62
- PRCT $79.30
- Resistance Level
- HIMS $33.14
- PRCT $92.92
- Average True Range (ATR)
- HIMS 2.70
- PRCT 4.06
- MACD
- HIMS -0.92
- PRCT -1.87
- Stochastic Oscillator
- HIMS 15.26
- PRCT 9.21
About HIMS Hims & Hers Health Inc.
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.